Abstract

JEG-3 is a human choriocarcinoma cell line characterized by low levels of adenosine deaminase expression. For the purpose of studying adenosine deaminase gene regulation in the JEG-3 cells, we attempted to select variant cells having increased adenosine deaminase expression. This was accomplished by selecting cells for resistance to the cytotoxic adenosine analogs 9-beta-D-arabinofuranosyl adenine (ara-A) or 9-beta-D-xylofuranosyl adenine (xyl-A), both of which could presumably be detoxified by the action of adenosine deaminase. Single step high dose selection was ineffective in obtaining cells with increased adenosine deaminase. However, multistep selection using either ara-A or xyl-A resulted in cell populations with increased adenosine deaminase activity. Removal of selective pressure resulted in decreased adenosine deaminase levels. Subclones of xyl-A-resistant cells belonged to one of three phenotypic classes characterized by either elevated adenosine deaminase levels, decreased adenosine kinase levels, or both of these features. One subclone (A3-1A7) with unaltered adenosine kinase expression showed a 20-fold increase in adenosine deaminase expression. Further selection of this subclone for increasing xyl-A resistance resulted in an additional 2-fold increase in adenosine deaminase expression, followed by loss of adenosine kinase expression. These adenosine kinase-deficient cells showed no subsequent increase in adenosine deaminase expression in response to further xyl-A selection pressure. These results confirmed that xyl-A toxicity was mediated through its phosphorylated form and indicated that resistance may result from increased adenosine deaminase levels and/or adenosine kinase deficiency. The increased adenosine deaminase expression of the A3-1A7 subclone was exclusively in the ADA 2 allelic form. However, cell fusion experiments between A3-1A7 cells and mouse C1-1D cells established the existence of functional copies of both ADA 1 and ADA 2 allelic genes in the A3-1A7 cells. The increased expression of only one of the two functional ADA alleles, the requirement for a stepwise selection protocol to obtain cells with increased adenosine deaminase, and the instability of the adenosine deaminase phenotype in the absence of selective pressure suggest that the alteration of adenosine deaminase phenotype in the drug-resistant cells was the result of adenosine deaminase gene amplification.

Highlights

  • JEG-3 isa human choriocarcinoma cell line charac- cells with increased adenosine deaminase, and the interized by low levels of adenosine deaminase expres- stability of the adenosine deaminase phenotype in the sion

  • For thepurpose of studying adenosine deaminase absence of selective pressure suggest that the alteragene regulation in the JEG-3 cells, we attempted to tion of adenosine deaminase phenotype in the drugselect variant cells having increased adenosine deam- resistant cells was the result of adenosine deaminase inase expression

  • One subclone mentally regulated in gastrointestinal tissues (stomach,large (A3-1A7)with unaltered adenosine kinase expression andsmallintestine)(5).Incontrast,thefetalpart of the showed a 20-fold increasein adenosine deaminase placenta is characterized by very low adenosine deaminase expression

Read more

Summary

IT Partially supported by National Institutes of Health Biology

The abbreviations used are: SCID, severe combined immunodeficiency disease; ara-A, 9-0-D-arabinofuranosyl adenine; xyl-A, 9-p-. D-xylofuranosyladenine; EHNA, erythro-9-(2-hydroxy-3-nonyl)-adenine; DMEM, Dulbecco’smodifiedEagle’smedium; Ino, inosine; Ado, adenosine; Hyp, hypoxanthine; HPLC, high pressure liquid chromatography; TCF, tissue conversion factor.

Gene Expression
Deaminase Activity
No of subclones
Gel phenotype
ADA T
Humaandenosine deaminase phenotype
DISCUSSION

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.